These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 32039032)
1. The Impact of Surgery in IDH 1 Wild Type Glioblastoma in Relation With the MGMT Deregulation. Marchi F; Sahnane N; Cerutti R; Cipriani D; Barizzi J; Stefanini FM; Epistolio S; Cerati M; Balbi S; Mazzucchelli L; Sessa F; Pesce GA; Reinert M; Frattini M Front Oncol; 2019; 9():1569. PubMed ID: 32039032 [No Abstract] [Full Text] [Related]
2. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389 [TBL] [Abstract][Full Text] [Related]
3. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter. Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247 [TBL] [Abstract][Full Text] [Related]
4. Correlation Between the Residual Tumor Volume, Extent of Tumor Resection, and O Sharma M; Bellamkonda S; Mohapatra S; Meola A; Jia X; Mohammadi A; Angelov L; Barnett GH; Vogelbaum M; Ahluwalia MS World Neurosurg; 2018 Aug; 116():e147-e161. PubMed ID: 29709748 [TBL] [Abstract][Full Text] [Related]
5. Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas. Gessler F; Bernstock JD; Braczynski A; Lescher S; Baumgarten P; Harter PN; Mittelbronn M; Wu T; Seifert V; Senft C Neurosurgery; 2019 Jan; 84(1):190-197. PubMed ID: 29617848 [TBL] [Abstract][Full Text] [Related]
6. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients? Pala A; Schmitz AL; Knoll A; Schneider M; Hlavac M; König R; Wirtz CR; Coburger J Clin Neurol Neurosurg; 2018 Apr; 167():6-10. PubMed ID: 29425743 [TBL] [Abstract][Full Text] [Related]
7. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea. Kim BS; Seol HJ; Nam DH; Park CK; Kim IH; Kim TM; Kim JH; Cho YH; Yoon SM; Chang JH; Kang SG; Kim EH; Suh CO; Jung TY; Lee KH; Kim CY; Kim IA; Hong CK; Yoo H; Kim JH; Kang SH; Kang MK; Kim EY; Kim SH; Chung DS; Hwang SC; Song JH; Cho SJ; Lee SI; Lee YS; Ahn KJ; Kim SH; Lim DH; Gwak HS; Lee SH; Hong YK Cancer Res Treat; 2017 Jan; 49(1):193-203. PubMed ID: 27384161 [TBL] [Abstract][Full Text] [Related]
8. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide. Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215 [TBL] [Abstract][Full Text] [Related]
9. DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients. Drexler R; Schüller U; Eckhardt A; Filipski K; Hartung TI; Harter PN; Divé I; Forster MT; Czabanka M; Jelgersma C; Onken J; Vajkoczy P; Capper D; Siewert C; Sauvigny T; Lamszus K; Westphal M; Dührsen L; Ricklefs FL Neuro Oncol; 2023 Feb; 25(2):315-325. PubMed ID: 35868257 [TBL] [Abstract][Full Text] [Related]
10. Prognostic value of Lam K; Eldred BSC; Kevan B; Pianka S; Eldred BA; Zapanta Rinonos S; Yong WH; Liau LM; Nghiemphu PL; Cloughesy TF; Green RM; Lai A Neurooncol Adv; 2022; 4(1):vdac030. PubMed ID: 35386566 [TBL] [Abstract][Full Text] [Related]
11. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas. Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161 [TBL] [Abstract][Full Text] [Related]
12. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study. Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280 [TBL] [Abstract][Full Text] [Related]
13. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study. Rapp M; Goeppert M; Felsberg J; Steiger HJ; Sabel M Br J Neurosurg; 2013 Aug; 27(4):430-5. PubMed ID: 23418781 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide. Younis SG; Khedr RA; El-Shorbagy SH J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634 [TBL] [Abstract][Full Text] [Related]
15. Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable Disease. Goldman J; Hagiwara A; Yao J; Raymond C; Ong C; Bakhti R; Kwon E; Farhat M; Torres C; Erickson LG; Curl BJ; Lee M; Pope WB; Salamon N; Nghiemphu PL; Ji M; Eldred BS; Liau LM; Lai A; Cloughesy TF; Chung C; Ellingson BM Front Oncol; 2022; 12():849993. PubMed ID: 35371980 [TBL] [Abstract][Full Text] [Related]
16. Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center. Haj A; Doenitz C; Schebesch KM; Ehrensberger D; Hau P; Putnik K; Riemenschneider MJ; Wendl C; Gerken M; Pukrop T; Brawanski A; Proescholdt MA Brain Sci; 2017 Dec; 8(1):. PubMed ID: 29295569 [TBL] [Abstract][Full Text] [Related]
17. Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study. Woo PYM; Ho JMK; Tse TPK; Lam SW; Mak CHK; Chan DTM; Lee MWY; Wong ST; Chan KY; Poon WS J Clin Neurosci; 2019 May; 63():134-141. PubMed ID: 30712777 [TBL] [Abstract][Full Text] [Related]
18. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy. Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791 [TBL] [Abstract][Full Text] [Related]
19. Prognostic analysis and nomogram construction for older patients with IDH-wild-type glioblastoma. Cao W; Xiong L; Meng L; Li Z; Hu Z; Lei H; Wu J; Song T; Liu C; Wei R; Shen L; Hong J Heliyon; 2023 Jul; 9(7):e18310. PubMed ID: 37519736 [TBL] [Abstract][Full Text] [Related]
20. The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials. Binabaj MM; Bahrami A; ShahidSales S; Joodi M; Joudi Mashhad M; Hassanian SM; Anvari K; Avan A J Cell Physiol; 2018 Jan; 233(1):378-386. PubMed ID: 28266716 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]